AAAAAA

   
Results: 1-10 |
Results: 10
A RANDOMIZED PHASE-II STUDY OF XELODA(TM) (CAPECITABINE) VS PACLITAXEL IN BREAST-CANCER PATIENTS FAILING PREVIOUS ANTHRACYCLINE THERAPY
Authors: MOISEYENKO V OREILLY SM TALBOT DC GORDON RJ GRIFFIN T OSTERWALDER B
Citation: V. Moiseyenko et al., A RANDOMIZED PHASE-II STUDY OF XELODA(TM) (CAPECITABINE) VS PACLITAXEL IN BREAST-CANCER PATIENTS FAILING PREVIOUS ANTHRACYCLINE THERAPY, Annals of oncology, 9, 1998, pp. 620-620
SOURCES OF ERROR IN TISSUE AND TUMOR MEASUREMENTS OF 5-[F-18]FLUOROURACIL
Authors: HARTE RJ MATTHEWS JC OREILLY SM PRICE PM
Citation: Rj. Harte et al., SOURCES OF ERROR IN TISSUE AND TUMOR MEASUREMENTS OF 5-[F-18]FLUOROURACIL, The Journal of nuclear medicine, 39(8), 1998, pp. 1370-1376
THE CHARING-CROSS-HOSPITAL EXPERIENCE WITH TEMOZOLOMIDE IN PATIENTS WITH GLIOMAS
Authors: NEWLANDS ES OREILLY SM GLASER MG BOWER M EVANS H BROCK C BRAMPTON MH COLQUHOUN I LEWIS P RICEEDWARDS JM ILLINGWORTH RD RICHARDS PG
Citation: Es. Newlands et al., THE CHARING-CROSS-HOSPITAL EXPERIENCE WITH TEMOZOLOMIDE IN PATIENTS WITH GLIOMAS, European journal of cancer, 32A(13), 1996, pp. 2236-2241
A WEEKLY ALTERNATING CHEMOTHERAPY REGIMEN WITH LOW TOXICITY FOR THE TREATMENT OF AGGRESSIVE LYMPHOMA
Authors: BOWER M BROCK C GULLIFORD T OREILLY SM SMITH DB NEWLANDS ES
Citation: M. Bower et al., A WEEKLY ALTERNATING CHEMOTHERAPY REGIMEN WITH LOW TOXICITY FOR THE TREATMENT OF AGGRESSIVE LYMPHOMA, Cancer chemotherapy and pharmacology, 38(1), 1996, pp. 106-109
DOSE INTENSIFICATION IN THE TREATMENT OF PATIENTS WITH TESTICULAR GERM-CELL TUMORS
Authors: OREILLY SM SMITH DB NEWLANDS ES RUSTIN GJS
Citation: Sm. Oreilly et al., DOSE INTENSIFICATION IN THE TREATMENT OF PATIENTS WITH TESTICULAR GERM-CELL TUMORS, European journal of cancer, 30A(5), 1994, pp. 723-723
MISMANAGEMENT OF CHORIOCARCINOMA DUE TO A FALSE LOW HCG MEASUREMENT
Authors: OREILLY SM RUSTIN GJS
Citation: Sm. Oreilly et Gjs. Rustin, MISMANAGEMENT OF CHORIOCARCINOMA DUE TO A FALSE LOW HCG MEASUREMENT, International journal of gynecological cancer, 3(3), 1993, pp. 186-188
TEMOZOLOMIDE - A NEW ORAL CYTOTOXIC CHEMOTHERAPEUTIC AGENT WITH PROMISING ACTIVITY AGAINST PRIMARY BRAIN-TUMORS
Authors: OREILLY SM NEWLANDS ES GLASER MG BRAMPTON M RICEEDWARDS JM ILLINGWORTH RD RICHARDS PG KENNARD C COLQUHOUN IR LEWIS P STEVENS MFG
Citation: Sm. Oreilly et al., TEMOZOLOMIDE - A NEW ORAL CYTOTOXIC CHEMOTHERAPEUTIC AGENT WITH PROMISING ACTIVITY AGAINST PRIMARY BRAIN-TUMORS, European journal of cancer, 29A(7), 1993, pp. 940-942
FLAVONE ACETIC-ACID (FAA) WITH RECOMBINANT INTERLEUKIN-2 (RIL-2) IN ADVANCED MALIGNANT-MELANOMA .1. CLINICAL AND VASCULAR STUDIES
Authors: OREILLY SM RUSTIN GJS FARMER K BURKE M HILL S DENEKAMP J
Citation: Sm. Oreilly et al., FLAVONE ACETIC-ACID (FAA) WITH RECOMBINANT INTERLEUKIN-2 (RIL-2) IN ADVANCED MALIGNANT-MELANOMA .1. CLINICAL AND VASCULAR STUDIES, British Journal of Cancer, 67(6), 1993, pp. 1342-1345
FLAVONE ACETIC-ACID (FAA) WITH RECOMBINANT INTERLEUKIN-2 (RIL-2) IN ADVANCED MALIGNANT MELANOMA-III - CYTOKINE STUDIES
Authors: HAWORTH C OREILLY SM CHU E RUSTIN GJS FELDMANN M
Citation: C. Haworth et al., FLAVONE ACETIC-ACID (FAA) WITH RECOMBINANT INTERLEUKIN-2 (RIL-2) IN ADVANCED MALIGNANT MELANOMA-III - CYTOKINE STUDIES, British Journal of Cancer, 67(6), 1993, pp. 1346-1350
FLAVONE ACETIC-ACID (FAA) WITH RECOMBINANT INTERLEUKIN-2 (RIL-2) IN ADVANCED MALIGNANT MELANOMA-IV - PHARMACOKINETICS AND TOXICITY OF FLAVONE ACETIC-ACID AND ITS METABOLITES
Authors: STRATFORD MRL RUSTIN GJS DENNIS MF WATFA RR HOWELLS N OREILLY SM
Citation: Mrl. Stratford et al., FLAVONE ACETIC-ACID (FAA) WITH RECOMBINANT INTERLEUKIN-2 (RIL-2) IN ADVANCED MALIGNANT MELANOMA-IV - PHARMACOKINETICS AND TOXICITY OF FLAVONE ACETIC-ACID AND ITS METABOLITES, British Journal of Cancer, 67(6), 1993, pp. 1351-1355
Risultati: 1-10 |